SubsidieMeestersImproving cancer therapy by identification of novel drug leads modulating transcription termination bridging molecular biology and therapeutic applications
The project aims to enhance cancer therapy by developing an automated screening platform to identify small molecule inhibitors that target transcription termination.
Projectdetails
Introduction
Our value proposition is improving cancer therapy by identification of novel anti-cancer candidate drug leads modulating transcription termination, bridging molecular cancer biology and therapeutic applications.
Methodology Development
We have developed a methodology to directly measure alterations in transcription termination.
Miniaturization and Automatization
Successfully, we subjected this methodology to miniaturization and automatization processes.
Funding Application
We are applying for funding to validate a screening platform to identify small molecule inhibitors of transcription termination.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-1-2026 |
| Einddatum | 30-6-2027 |
| Subsidiejaar | 2026 |
Partners & Locaties
Projectpartners
- UNIWERSYTET IM. ADAMA MICKIEWICZA WPOZNANIUpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Cancer cell plasticity on targeted therapyThis project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes. | ERC Consolid... | € 2.000.000 | 2022 | Details |
INhibiting mechanoTRansduction as a novel approach for Oncology theraPY (INTROPY)This project aims to develop a first-in-class mechanoinhibitor drug targeting stiffness-induced protein unfolding in solid tumors, with potential applications in cancer therapy and fibrosis. | ERC Proof of... | € 150.000 | 2025 | Details |
Detecting epigenetic biomarkers in the blood for non-invasive precision oncologyDevelop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution. | ERC Starting... | € 1.500.000 | 2022 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Cancer cell plasticity on targeted therapy
This project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes.
INhibiting mechanoTRansduction as a novel approach for Oncology theraPY (INTROPY)
This project aims to develop a first-in-class mechanoinhibitor drug targeting stiffness-induced protein unfolding in solid tumors, with potential applications in cancer therapy and fibrosis.
Detecting epigenetic biomarkers in the blood for non-invasive precision oncology
Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment
3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Voorkomen van therapieresistentie bij kankerDit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Voorkomen van therapieresistentie bij kanker
Dit project onderzoekt een bloedgebaseerde methode voor vroege detectie van therapieresistentie bij kanker om levensverwachting te verbeteren.